Lutetium LU 177 Vipivoride Tetraxetan (Pluvicto®)
This is a radiopharmaceutical medication. It binds with cancer cells that express prostate-specific membrane antigen in metastatic castration-resistant prostate cancer and delivers radiation directly to cancer cells. The radiation damages the DNA of the tumor cells, causing them to die or stop growing. Because the radiation is given directly to the tumor, the damage to surrounding tissues is minimized.